176 related articles for article (PubMed ID: 25644680)
1. Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis.
Luo L; Yuan X; Huang W; Ren F; Zhu H; Zheng Y; Tang L
Intern Med J; 2015 May; 45(5):546-57. PubMed ID: 25644680
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
Cook JR; Yin D; Alemao E; Drummond M
Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
[TBL] [Abstract][Full Text] [Related]
3. Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis.
Hameed I; Shah SA; Aijaz A; Mushahid H; Farhan SH; Dada M; Khan AB; Amjad R; Alvi F; Murtaza M; Zuberi Z; Hamza M
Am J Cardiovasc Drugs; 2024 May; 24(3):419-431. PubMed ID: 38578578
[TBL] [Abstract][Full Text] [Related]
4. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
7. Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.
Wallach-Kildemoes H; Hansen EH
Eur J Clin Pharmacol; 2015 Oct; 71(10):1245-54. PubMed ID: 26227068
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe: new preparation. A cholesterol-lowering drug with no clinical advantage.
Prescrire Int; 2004 Oct; 13(73):176-9. PubMed ID: 15499698
[TBL] [Abstract][Full Text] [Related]
9. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.
Sahebkar A; Simental-Mendía LE; Pirro M; Banach M; Watts GF; Sirtori C; Al-Rasadi K; Atkin SL
Sci Rep; 2018 Dec; 8(1):17887. PubMed ID: 30552391
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe-Statin Combination Therapy.
Nußbaumer B; Glechner A; Kaminski-Hartenthaler A; Mahlknecht P; Gartlehner G
Dtsch Arztebl Int; 2016 Jul; 113(26):445-53. PubMed ID: 27412989
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
Ma YB; Chan P; Zhang Y; Tomlinson B; Liu Z
Expert Opin Pharmacother; 2019 Jun; 20(8):917-928. PubMed ID: 30908086
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
16. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe: a novel option for lowering cholesterol.
Davidson MH
Expert Rev Cardiovasc Ther; 2003 May; 1(1):11-21. PubMed ID: 15030293
[TBL] [Abstract][Full Text] [Related]
18. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
19. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
